D.E. Shaw & Co’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-308,104
| Closed | -$265K | – | 3491 |
|
|
2023
Q4 | $265K | Sell |
308,104
-14,368
| -4% | -$12.3K | ﹤0.01% | 2603 |
|
|
2023
Q3 | $345K | Sell |
322,472
-32,418
| -9% | -$34.7K | ﹤0.01% | 2424 |
|
|
2023
Q2 | $919K | Buy |
354,890
+77,816
| +28% | +$202K | ﹤0.01% | 2122 |
|
|
2023
Q1 | $1.13M | Buy |
277,074
+154,118
| +125% | +$629K | ﹤0.01% | 2133 |
|
|
2022
Q4 | $617K | Sell |
122,956
-16,301
| -12% | -$81.8K | ﹤0.01% | 2632 |
|
|
2022
Q3 | $1.82M | Sell |
139,257
-21,608
| -13% | -$283K | ﹤0.01% | 2181 |
|
|
2022
Q2 | $2.06M | Buy |
160,865
+97,468
| +154% | +$1.25M | ﹤0.01% | 2230 |
|
|
2022
Q1 | $967K | Buy |
63,397
+3,366
| +6% | +$51.3K | ﹤0.01% | 2896 |
|
|
2021
Q4 | $1.06M | Buy |
60,031
+14,953
| +33% | +$265K | ﹤0.01% | 2706 |
|
|
2021
Q3 | $948K | Sell |
45,078
-60
| -0.1% | -$1.26K | ﹤0.01% | 2518 |
|
|
2021
Q2 | $890K | Buy |
45,138
+34,950
| +343% | +$689K | ﹤0.01% | 2572 |
|
|
2021
Q1 | $296K | Buy |
+10,188
| New | +$296K | ﹤0.01% | 2671 |
|